Cantor Fitzgerald Forecasts MannKind FY2025 Earnings

MannKind Co. (NASDAQ:MNKD) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for MannKind in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer expects that the biopharmaceutical company will earn $0.34 per share for the year. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.04. The business had revenue of $70.08 million for the quarter, compared to analyst estimates of $77.27 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%.

MNKD has been the topic of a number of other reports. StockNews.com lowered shares of MannKind from a “buy” rating to a “hold” rating in a research report on Saturday, December 7th. Wells Fargo & Company began coverage on MannKind in a report on Friday, December 20th. They set an “overweight” rating and a $9.00 price objective on the stock. Finally, Royal Bank of Canada upgraded MannKind from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $7.00 to $10.00 in a report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $9.07.

MannKind Price Performance

MNKD stock opened at $6.03 on Thursday. The company has a market capitalization of $1.66 billion, a PE ratio of 86.14 and a beta of 1.29. MannKind has a 12 month low of $3.17 and a 12 month high of $7.63. The firm’s 50-day moving average is $6.47 and its 200 day moving average is $6.26.

Hedge Funds Weigh In On MannKind

Several institutional investors and hedge funds have recently bought and sold shares of MNKD. Millennium Management LLC boosted its position in shares of MannKind by 189.8% in the 2nd quarter. Millennium Management LLC now owns 4,744,519 shares of the biopharmaceutical company’s stock worth $24,766,000 after purchasing an additional 3,107,598 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in MannKind in the third quarter valued at about $12,252,000. Two Sigma Advisers LP boosted its holdings in MannKind by 60.7% in the third quarter. Two Sigma Advisers LP now owns 2,648,327 shares of the biopharmaceutical company’s stock worth $16,658,000 after acquiring an additional 1,000,600 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of MannKind by 37.1% during the third quarter. Parkman Healthcare Partners LLC now owns 3,304,085 shares of the biopharmaceutical company’s stock worth $20,783,000 after acquiring an additional 894,486 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of MannKind by 421.3% during the third quarter. BNP Paribas Financial Markets now owns 471,802 shares of the biopharmaceutical company’s stock valued at $2,968,000 after acquiring an additional 381,298 shares in the last quarter. 49.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at MannKind

In other MannKind news, Director Steven B. Binder sold 67,536 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $6.89, for a total value of $465,323.04. Following the completion of the transaction, the director now directly owns 1,075,026 shares in the company, valued at approximately $7,406,929.14. The trade was a 5.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Stuart A. Tross sold 55,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total transaction of $403,700.00. Following the sale, the insider now directly owns 967,191 shares of the company’s stock, valued at approximately $7,099,181.94. The trade was a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 190,075 shares of company stock valued at $1,325,587. Corporate insiders own 3.00% of the company’s stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.